AG真人官方

HOOKIPA Pharma Inc. (NASDAQ: HOOK) has filed Post-Effective Amendment No. 1 to four previously effective Form S-8 registration statements. The company is deregistering all unsold shares that had been reserved for issuance under its 2018, 2019 and 2023 equity compensation and ESPP plans. The action follows shareholder approval on 29 Jul 2025 of both (1) an Asset Purchase Agreement with Gilead Sciences covering what may be substantially all of HOOKIPA鈥檚 assets and (2) a Plan of Dissolution. As the company now intends to liquidate and dissolve, it is terminating any further offerings under the affected registration statements and removing from registration the remaining shares (no reverse-split adjustment applied in counts).

The filing contains no financial results, but it confirms the end of HOOKIPA鈥檚 equity incentive programs and signals that the company will wind down operations once the asset sale closes and dissolution begins. There is no impact on outstanding shares already issued; the amendment solely affects unsold, unissued shares registered for future employee grants. Management states the filing satisfies the undertaking in Part II of each S-8 to remove such securities upon termination of the offerings.

Qorvo, Inc. (QRVO) insider Gina Harrison, the company’s Vice President & Corporate Controller, filed a Form 4 covering a single transaction dated 07 July 2025.

• Transaction code F indicates shares were withheld by the issuer to cover taxes due upon the vesting of equity awards.
• Shares affected: 133 common shares at $88.78 each.
• Post-transaction ownership: Harrison now holds 24,751 common shares directly.

No derivative securities were involved, and the filing shows no additional purchases or sales. The activity is routine, immaterial to the company’s capital structure, and does not signal a strategic shift.

Qorvo, Inc. (ticker QRVO) has submitted an Annual Report to Shareholders (Form ARS) to the U.S. Securities and Exchange Commission. The filing, accepted on 26 June 2025, is available only as a PDF and the text provided here contains no financial tables, earnings data or management discussion. Investors must review the linked PDF to obtain the company鈥檚 full operating and financial results for the fiscal year. As presented, this notice is a routine compliance disclosure without immediate analytical value.

Qorvo (QRVO) filed Definitive Additional Proxy Materials (DEFA14A) for its 2025 Annual Meeting set for August 13, 2025. The notice covers ten director nominees, an advisory vote on executive compensation, amendments to the 2022 Stock Incentive Plan and 2007 Employee Stock Purchase Plan, ratification of Ernst & Young as auditor, and a shareholder proposal on special meeting rights that the board recommends AGAINST. No new financial data, strategy shifts or material transactions were disclosed; the document mainly provides voting instructions, deadlines (online voting by August 12, 2025) and access to full proxy materials. No filing fee was required.

Qorvo has announced its 2025 Annual Meeting of Stockholders to be held on August 13, 2025 at 8:00 a.m. CDT in Plano, TX. The meeting will address several key proposals including:

• Election of 10 director nominees for one-year terms
• Non-binding advisory vote on Named Executive Officer compensation
• Approval of amended 2022 Stock Incentive Plan
• Approval of amended 2007 Employee Stock Purchase Plan
• Ratification of Ernst & Young LLP as independent auditor
• Advisory vote on a shareholder proposal regarding special meetings

The Board recommends voting "FOR" all nominees and proposals 2-5, and "AGAINST" proposal 6. Stockholders of record as of June 20, 2025 are eligible to vote. Proxy materials were distributed starting June 26, 2025. Shareholders can vote via mail, phone, internet, or in person at the meeting. The company has engaged Innisfree M&A as proxy solicitor to assist with the voting process.